Treatment of chronic enteritis by a combination of fungicides

I. Pathological mechanisms and the state of chronic enteritis. The intestinal strain plays a key role in it, and normally the intestinal fungus is balanced with the harmful fungus, which together preserves the intestinal function. However, among chronic enteritis patients, the balance of intestinal strains has been broken due to chronic eating irregularities, infections, immunopathy, etc., the excessive proliferation of harmful bacteria such as coli and salmonella, and the relative decrease in the number of beneficial bacteria has led to a continuous inflammatory response to intestinal mucosa, resulting in impairment of intestinal mucous barrier, intestinal pervulsions and digestive assimilation, and a high incidence of abdominal pain, diarrhoea, abdominal abdominal swelling and muletal sepsis, as well as the persistence of these conditions, which seriously affect the quality of life and physical health of the patients, placing a heavy physical and psychological burden on the patients and increasing the consumption of medical resources. The use of antibacterial drugs is aimed at the targeted eradication or suppression of pathogens that cause intestinal inflammation, thereby reducing the inflammation of the enteric tract. When it is clear that chronic enteritis is caused by specific bacterial infections, such as pseudofilmary enteritis resulting from hard-to-scrutinosis infections, a reasonable choice of antibacterial drugs can quickly control the source of infection and mitigate the acute symptoms of a patient, such as the use of antibacterials that are particularly effective for hard-to-scorcia, such as metazine and vancomicin, can reduce the number of intestinal pathogens in the short term, reduce the inflammation damage to intestinal mucular membranes and reduce to some extent the symptoms of diarrhoea, abdominal pain, etc. of the patient. However, there are limitations to the application of antibacterial drugs. On the one hand, anti-bacterial drugs tend to cause extensive damage to normal strains in the intestinal tract, while eliminating harmful bacteria, further exacerbating intestinal herbology disorders. This not only affects the normal digestive, absorption and immune functions of the intestinal tract, but may also create breeding opportunities for other drug-resistant or condition-induced bacteria, leading to secondary infections, such as long-term use of broad-spectrum antibacterial drugs, which may lead to fungi infections, such as pyrochlor. On the other hand, with the widespread use of antibacterial drugs, the problem of bacterial resistance has increased, reducing the efficacy of some antibacterial drugs, making chronic intestine treatment more difficult and complex, while also extending the patient ‘ s pathology and recovery. iii. The beneficial effects and mechanisms of the prophylactic bacteria on chronic enteritis. Common prophylactic bacteria, such as bipolar, acidic and Bulgarian Bacillus, play an active role in intestinal health through various mechanisms. First, it can inhibit the growth and planting of harmful bacteria through competition for nutrients and sticky points. For example, cosmobilism can form a biological barrier on the face of the intestinal mucous membrane, which prevents the combination of pathogens such as cosmophilus, salmonella, and intestinal mucous cells, thereby reducing the impact and damage to the intestinal mucous membranes and reducing the risk of intestinal inflammation response. Secondly, biogenic bacteria can produce a variety of beneficial metabolites, such as organic acid (lactic acid, acetic acid, etc.), hydrogen peroxide, bacterialin, etc. These metabolites can reduce local pH values in the intestinal tract, create an acidic environment that is not conducive to the growth of harmful bacteria while directly inhibiting the growth and reproduction of harmful bacteria and acting as anti-inflammatory agents. In addition, part of the fungi can promote intestinal mucous cell scrinosis, enhance the integrity of the intestinal mucous barrier, further deter intrusion of harmful substances and pathogens and protect the intestinal tract from inflammation. Moreover, the prophylactic bacteria play an important role in regulating the intestinal immune function. They stimulate the growth and maturity of lymphocyte-related lymphocyte tissues in the intestinal tract, promote the activity and differentiation of immunocellular cells such as megacormic cells, T lymphocytes and B lymphocytes, regulate the genre of immunokinetic factors such as white cell media, interferents, tumor necrosis, etc., and enhance the intestinal immune defence, while inhibiting over-immunitis reactions and rebalancing intestinal immune functions, thus helping to mitigate the symptoms of chronic intestinal inflammation and promoting the rehabilitation and healing of intestinal tissues. Co-benefits and implementation points for joint antibacterial treatment Antibacterial drugs are responsible for the rapid control of pathogen infections, the reduction of acute symptoms of intestinal inflammation and the creation of favourable conditions for subsequent treatment, while the probative bacteria focus on the restoration and maintenance of micro-ecological balance of the intestinal tract, the enhancement of the intestinal mucous barrier, the improvement of the intestinal ability to immunize, the reduction of adverse reactions from the use of antibacterial drugs and the prevention of relapse. In the implementation of joint treatment, the following key points require attention. The first is the reasonable choice of the type and formulation of antibacterial drugs and prophylactic bacteria. Efficient, low-toxic, well-targeted antibacterial drugs should be selected with appropriate prophylactic formulations, depending on the patient ‘ s specific condition, the type of fungi, the results of the drug-sensitive tests and the intestinal population. For example, for patients with more severe intestinal mucous membrane impairments, it is possible to select a fungi with good intestinal muccultation and restoration; for patients with specific pathogen infections, it is chosen to use antibacterial drugs that are sensitive to the pathogen to strike precisely. The second is the timing and sequence of good medicine. It is generally recommended that the fungi be given at intervals of time (usually 2 – 3 hours) after the use of an antibacterial drug in order to avoid direct inhibition or extinction of the antibacterial drug on the activity of the fungi. This will ensure that the fungi survive and play a beneficial role in a relatively stable environment within the intestinal tract and achieve synergies between the two. Thirdly, care is taken about the rationality of drug use and treatment. Appropriate doses of antibacterial drugs and prophylactic bacteria should be accurately calculated and treated according to the patient ‘ s age, weight, severity of the condition and liver and kidney function, and in accordance with the prescribed course of treatment. Avoiding poor or repeated treatments due to underdoses, while also preventing excessive doses from causing adverse reactions and bacterial resistance. For fungi, it is important to ensure that a sufficient number of live bacteria reach and are planted in order to perform their role in regulating the micro-ecological aspects of the intestinal tract, but care is taken not to overuse them in order to create new imbalances in intestinal micro-ecology. Fourth is the strengthening of comprehensive management and health education for patients. During combined treatment, the patient should be instructed to maintain good eating habits, avoid consumption of spicy, greasy, irritating and cold food, quit smoking and alcohol, ensure adequate sleep and appropriate exercise to enhance the immune and intestinal digestive function of the body, and promote the rehabilitation and rehabilitation of the intestine. At the same time, the purpose, methodology and care of joint treatment are explained in detail to the patient, so as to increase his/her dependence and ensure the smooth implementation of the treatment programme. In conclusion, the treatment of chronic enteroitis by a combination of antibacterial drugs is a comprehensive treatment strategy of great promise and application. By taking full advantage of both, and overcoming their respective limitations, it is possible to control intestinal inflammation more effectively, repair the micro-ecological balance of the intestinal intestine, improve the treatment of chronic intestinal inflammation, improve the quality of life of patients and open a new and effective path to the treatment of chronic intestinal inflammation. However, there are still a number of issues that require further research and optimization in the joint treatment programme, such as the best combination of drugs, precision determination of the dosage and course of treatment, long-term efficacy and safety assessment of joint treatment, and more clinical research and practical exploration in the future to continuously refine this treatment model to bring more evangelization to chronic enteritis patients.